Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?

Hallucinations arise from at least three distinct pharmacological pathways: activation of dopamine D2 receptors by psychostimulants, activation of serotonin 5HT2A receptors by psychedelics, and blockage of glutamate NMDA receptors by dissociative anesthetics. In schizophrenia, the relative roles of NMDA and dopamine receptors remain debated, and slight clinical differences appear depending on the cause. This narrative review synthesizes how leading researchers have approached whether the concept of hallucination is clinically and neurobiologically homogeneous. Some favor a single mechanism, while others propose integrated theories based on pharmacological psychosis models. The authors suggest that although common neurobiological pathways may exist, each system likely has unique properties that explain observed clinical differences.

Study at a glance

Abstract

Hallucinations are complex misperceptions, that principally occur in schizophrenia or after intoxication induced by three main classes of drugs: psychostimulants, psychedelics, and dissociative anesthetics. There are at least three different pharmacological ways to induce hallucinations: (1) activation of dopamine D2 receptors (D2Rs) with psychostimulants, (2) activation of serotonin 5HT2A receptors (HT2ARs) with psychedelics, and (3) blockage of glutamate NMDA receptors (NMDARs) with dissociative anesthetics. In schizophrenia, the relative importance of NMDAR and D2R in the occurrence of hallucinations is still debated. Slight clinical differences are observed for each etiology. Thus, we investigated whether the concept of hallucination is homogenous, both clinically and neurobiologically. A narrative review of the literature is proposed to synthesize how the main contributors in the field have approached and tried to solve these outstanding questions. While some authors prefer one explanatory mechanism, others have proposed more integrated theories based on the different pharmacological psychosis models. In this review, such theories are discussed and faced with the clinical data. In addition, the nosological aspects of hallucinations and psychosis are addressed. We suggest that if there may be common neurobiological pathways between the different pharmacological systems that are responsible for the hallucinations, there may also be unique properties of each system, which explains the clinical differences observed.